VSTM
Verastem, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.20
+2.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
Market Cap
$742.62M
MomentumView details →
1D Return
+2.76%
YTD Return
+1.81%
RSI (14)
67.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
Market Cap
$742.62M
RSI (14)
67.6
MomentumView details →
1D Return
+2.76%
YTD Return
+1.81%
SummaryUpdated Jun 1, 2026
Verastem, Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company founded in 2010 and headquartered in Needham, Massachusetts. The company went public in January 2012 and focuses on developing innovative cancer treatments through targeted therapies. Verastem operates as a clinical-stage biotechnology firm, meaning it does not yet have approved products generating commercial revenue, but instead invests heavily in research and development to advance promising drug candidates through clinical trials toward potential FDA approval.
Similar companies
Latest newsMore news →
Verastem, Inc. amended its Note Purchase Agreement on August 6, 2026, restructuring existing notes and adding a new series of up to $75 million in revenue-based notes.29d agoVerastem reported a second-quarter loss of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 and improving from a loss of $0.39 per share a year earlier.29d ago